Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival.
Etoposide
Hemophagocytic syndrome
Hospital acquired infections
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
28 Oct 2022
28 Oct 2022
Historique:
received:
06
07
2022
accepted:
15
10
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Etoposide remains the cornerstone of symptomatic management of critically ill patients with secondary hemophagocytic syndrome (sHS). Risk of healthcare-associated infections (HAIs) in this setting with etoposide has never been assessed. We sought to evaluate the association between etoposide administration, HAIs occurrence and survival in critically ill adult patients with sHS. In this retrospective single-center study conducted in a university hospital ICU between January 2007 and March 2020, all consecutive patients with sHS were included. HAIs were defined as any microbiologically documented infection throughout ICU stay. Competing risk survival analysis was performed to determine factors associated with HAIs. Propensity score-based overlap weighting was performed to adjust for factors associated with etoposide use. 168 patients with a median age of 49 [38, 59] were included. Forty-three (25.6%) patients presented with at least 1 microbiologically documented HAI throughout ICU stay. After adjustment, cumulative incidence of HAI was higher in patients receiving etoposide (p = 0.007), while survival was unaffected by etoposide status (p = 0.824). By multivariable analysis, etoposide treatment was associated with a higher incidence of HAIs (sHR 3.75 [1.05, 6.67]), whereas no association with survival (sHR 0.53 [0.20, 1.98]) was found. Other factors associated with increased mortality after adjustment included age, immunodepression, male sex, SOFA score > 13, and occurrence of HAI. In patients with sHS, etoposide treatment is independently associated with increased occurrence of HAIs, whereas no association with survival was found. Intensivists should be aware of increased infectious risk, to promptly detect and treat infections in this specific setting. Studies to assess benefits from prophylactic anti-infectious agents in this setting are warranted and the lack of benefit of etoposide on survival needs to be interpreted cautiously.
Sections du résumé
BACKGROUND
BACKGROUND
Etoposide remains the cornerstone of symptomatic management of critically ill patients with secondary hemophagocytic syndrome (sHS). Risk of healthcare-associated infections (HAIs) in this setting with etoposide has never been assessed. We sought to evaluate the association between etoposide administration, HAIs occurrence and survival in critically ill adult patients with sHS. In this retrospective single-center study conducted in a university hospital ICU between January 2007 and March 2020, all consecutive patients with sHS were included. HAIs were defined as any microbiologically documented infection throughout ICU stay. Competing risk survival analysis was performed to determine factors associated with HAIs. Propensity score-based overlap weighting was performed to adjust for factors associated with etoposide use.
RESULTS
RESULTS
168 patients with a median age of 49 [38, 59] were included. Forty-three (25.6%) patients presented with at least 1 microbiologically documented HAI throughout ICU stay. After adjustment, cumulative incidence of HAI was higher in patients receiving etoposide (p = 0.007), while survival was unaffected by etoposide status (p = 0.824). By multivariable analysis, etoposide treatment was associated with a higher incidence of HAIs (sHR 3.75 [1.05, 6.67]), whereas no association with survival (sHR 0.53 [0.20, 1.98]) was found. Other factors associated with increased mortality after adjustment included age, immunodepression, male sex, SOFA score > 13, and occurrence of HAI.
CONCLUSIONS
CONCLUSIONS
In patients with sHS, etoposide treatment is independently associated with increased occurrence of HAIs, whereas no association with survival was found. Intensivists should be aware of increased infectious risk, to promptly detect and treat infections in this specific setting. Studies to assess benefits from prophylactic anti-infectious agents in this setting are warranted and the lack of benefit of etoposide on survival needs to be interpreted cautiously.
Identifiants
pubmed: 36307626
doi: 10.1186/s13613-022-01075-9
pii: 10.1186/s13613-022-01075-9
pmc: PMC9616615
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101Informations de copyright
© 2022. The Author(s).
Références
Pediatr Crit Care Med. 2000 Jul;1(1):51-4
pubmed: 12813287
Crit Rev Oncol Hematol. 2017 Jun;114:1-12
pubmed: 28477737
Br J Haematol. 2015 Jan;168(1):63-8
pubmed: 25157895
Am J Kidney Dis. 2015 Jun;65(6):851-9
pubmed: 25480521
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Chest. 2016 May;149(5):1294-301
pubmed: 26836913
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Am J Infect Control. 1997 Dec;25(6):458-62
pubmed: 9437483
Am J Epidemiol. 2019 Jan 1;188(1):250-257
pubmed: 30189042
JAMA. 2020 Jun 16;323(23):2417-2418
pubmed: 32369102
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
J Clin Oncol. 2001 May 15;19(10):2665-73
pubmed: 11352958
Indian J Crit Care Med. 2012 Oct;16(4):198-203
pubmed: 23559726
J Neuropathol Exp Neurol. 2019 Mar 1;78(3):197-208
pubmed: 30726926
Hematol Oncol. 2021 Feb;39(1):114-122
pubmed: 33099794
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265
Medicine (Baltimore). 2015 Oct;94(40):e1692
pubmed: 26448017
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Crit Care Med. 2020 Nov;48(11):e1137-e1146
pubmed: 32947471
Blood. 2017 Dec 21;130(25):2728-2738
pubmed: 28935695
Support Care Cancer. 2020 Jan;28(1):193-200
pubmed: 31001694
Korean J Hematol. 2012 Dec;47(4):273-80
pubmed: 23320006
Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e373-e380
pubmed: 30037588